CTI BIOPHARMA: PACRITINIB PHASE 3 STUDY SHOWS POSITIVE RESULTS IN PATIENT REPORTED OUTCOMES MEASURING QUALITY OF LIFE IN PATIENTS WITH MYELOFIBROSIS

Protocollo
3476
Comunicato
20150612_3476.pdf
Azienda
CTI BIOPHARMA
Tipo
Comunicato
SDIR
SDIRNIS
Lingua
ENG
Data creazione
Data ricezione SDIR
Data diffusione SDIR
Mercato
Euronext Milan